Hatteras Venture Partners
Early-stage venture capital firm focused on building companies in transformative human medicine and disruptive healthcare technologies. Hatteras emphasizes a replicable, risk‑mitigated value-creation model and invests across biopharma, medical devices, diagnostics and healthcare IT from pre-clinical through early commercial stages. The firm is active nationally and participates as lead investor in rounds and in board-level engagement.
Industries
Nr. of Employees
small (1-50)
Hatteras Venture Partners
Portfolio
Developing a versatile epigenetic editing platform using multiple effectors.
#Biopharma / Gene editing (epigenetic editing)
Developing an extracardiac, extravascular approach to cardiac pacing and defibrillation.
#Medical Device / Cardiac devices
Advance Care Planning solutions delivering improved outcomes, member experience and cost savings for plans.
#Healthcare IT / Services
AAV gene therapy company focused on reversing or preventing blindness.
#Biopharma / Gene therapy
Developing engineered AAV vectors that can evade neutralizing antibodies.
#Biopharma / Gene therapy
Developing small-molecule therapies to address unmet needs in oncology.
#Biopharma / Oncology
Developing a versatile epigenetic editing platform using multiple effectors.
#Biopharma / Gene editing (epigenetic editing)
Developing an extracardiac, extravascular approach to cardiac pacing and defibrillation.
#Medical Device / Cardiac devices
Advance Care Planning solutions delivering improved outcomes, member experience and cost savings for plans.
#Healthcare IT / Services
AAV gene therapy company focused on reversing or preventing blindness.
#Biopharma / Gene therapy
Developing engineered AAV vectors that can evade neutralizing antibodies.
#Biopharma / Gene therapy
Developing small-molecule therapies to address unmet needs in oncology.
#Biopharma / Oncology